Disclosed are imidazopyrazine compounds of formula (I), salts thereof, and methods for their preparation. Specific examples of compounds of Formula (I) include: 4-{ 8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yll-N-[2-(dimethylamino)ethyl]benzamide 5-{ 8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl} pyridine-3-carboxamide 4-({ 3-[8-(1H-Indazol-6-ylamino)-imidazo[1,2-a]pyrazin-6-yl]benzene} amido)benzoic acid. Compounds of Formula (I) are inhibitors of spleen tyrosine kinase (Syk). The compounds are useful for treating a disease responsive to the inhibition of Syk activity selected from the group comprising allergic disorders, autoimmune diseases and inflammatory diseases such as: SLE, rheumatoid arthritis, multiple vasculitides, idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDs) and asthma.
